Accelerated Approval Program’s Future Is On The Line At Avastin Hearing

Genentech and FDA’s Center for Drug Evaluation and Research seem to agree on one thing when it comes to deciding whether Avastin’s (bevacizumab) metastatic breast cancer indication should be withdrawn – the integrity and intent of the agency’s accelerated approval program are at stake.